Iron dysregulation and Parkinson's disease

Journal of Alzheimer's Disease

Volumn 6, Issue SUPPL., 2004, Pages

  Andersen, Julie K ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

Iron; Iron regulatory proteins; Oxidative stress; Parkinson's disease

Indexed keywords

IRON REGULATORY FACTOR;

ARTICLE; BRAIN LEVEL; CELL LEVEL; DOPAMINERGIC NERVE CELL; HOMEOSTASIS; HUMAN; IRON METABOLISM; MESENCEPHALON; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

EID: 13444274645     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/jad-2004-6s602     Document Type: Article

References (73)

1. S.F. Ali, S.N. David and G.D. Newport, Age-related susceptibility to MPTP-induced neurotoxicity in mice, Neurotoxicology 14 (1993), 29-34.
2. S.F. Ali, S.N. David, G.D. Newport, J.L. Cadet and W. Slikker, Jr., MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels, Synapse 18 (1994), 27-34.
3. C. Anderson, H. Checkoway, G.M. Franklin, S. Beresford, T. Smith-Weller and P.D. Swanson, Dietary factors in Parkinson's disease: the role of food groups and specific foods, Mov Disord 14 (1999), 21-27.
4. J. Ara, S. Przedborski, A.B. Naini, V. Jackson-Lewis, R.R. Trifiletti, J. Horwitz and H. Ischiropoulos, Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP), Proc Natl Acad Sci USA 95 (1998), 7659-7663.
5. C. Bouton, M.J. Chauveau, S. Lazereg and J.C. Drapier, Recycling of RNA binding iron regulatory protein 1 into an aconitase after nitric oxide removal depends on mitochondrial ATP, J Biol Chem 277 (2002), 31220-31227.
6. C. Bouton and J.C. Drapier, Iron regulatory proteins as NO signal transducers, Sci STKE pe17, 2003.
7. C. Bouton, M. Raveau and J.C. Drapier, Modulation of iron regulatory protein functions. Further insights into the role of nitrogen- and oxygen-derived reactive species, J Biol Chem 271 (1996), 2300-2306.
8. Q. Chen, J.R. Connor and J.L. Beard, Brain iron, transferrin and ferritin concentrations are altered in developing iron-deficient rats, J Nutr 125 (1995), 1529-1535.
9. K.K. Chung, T.M. Dawson, B. Thomas, X. Li, O. Pletnikova, J.C. Troncoso, L. Marsh and V.L. Dawson, S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function, Science, 2004.
10. I. Date, D.L. Felten and S. Y. Felten, Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis, Brain Res 519 (1990), 266-276.
11. D.T. Dexter, A. Carayon, F. Javoy-Agid, Y. Agid, F.R. Wells, S.E. Daniel, A.J. Lees, P. Jenner and C.D. Marsden, Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia, Brain 114(Pt 4) (1991), 1953-1975.
12. D.T. Dexter, J. Sian, P. Jenner and C.D. Marsden, Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia, Adv Neurol 60 (1993), 273-281.
13. S. Dimmeler, V. Rippmann, U. Weiland, J. Haendeler and A.M. Zeiher, Angiotensin II induces apoptosis of human endothelial cells, Protective effect of nitric oxide, Circ Res 81 (1997), 970-976.
14. J.C. Drapier, H. Hirling, J. Wietzerbin, P. Kaldy and L.C. Kuhn, Biosynthesis of nitric oxide activates iron regulatory factor in macrophages, Embo J 12 (1993), 3643-3649.
15. A.J. Dwork, G. Lawler, P.A. Zybert, M. Durkin, M. Osman, N. Willson and A.I. Barkai, An autoradiographic study of the uptake and distribution of iron by the brain of the young rat, Brain Res 518 (1990), 31-39.
16. R.S. Eisenstein, Iron regulatory proteins and the molecular control of mammalian iron metabolism, Annu Rev Nutr 20 (2000), 627-662.
17. B.A. Faucheux, M.E. Martin, C. Beaumont, S. Hunot, J.J. Hauw, Y. Agid and B.C. Hirsch, Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease, J Neurochem 83 (2002), 320-330.
18. C. Fillebeen and K. Pantopoulos, Redox control of iron regulatory proteins, Redox Rep 1 (2002), 15-22.
19. M. Gassen and M.B. Youdim, The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders, Pharmacol Toxicol 80 (1997), 159-166.
20. M. Gerlach, D. Ben-Shachar, P. Riederer and M.B. Youdim, Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63 (1994), 793-807.
21. M. Gerlach, K. Double, P. Riederer, E. Hirsch, K. Jellinger, P. Jenner, A. Trautwein and M.B. Youdim, Iron in the Parkinsonian substantia nigra, Mov Disord 12 (1997), 258-260.
22. B.I. Giasson, J.E. Duda, I.V. Murray, Q. Chen, J.M. Souza, H.I. Hurtig, H. Ischiropoulos, J.Q. Trojanowski and V.M. Lee, Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions, Science 290 (2000), 985-989.
23. B.I. Giasson, R. Jakes, M. Goedert, J.E. Duda, S. Leight, J.Q. Trojanowski and V.M. Lee, A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease, J Neurosci Res 59 (2000), 528-533.
24. J.M. Gorell, C.C. Johnson, B.A. Rybicki, E.L. Peterson, G.X. Kortsha, G.G. Brown and R.J. Richardson, Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease, Neurotoxicology 20 (1999), 239-247.
25. M. Gupta, B.K. Gupta, R. Thomas, V. Bruemmer, J.R. Sladek, Jr. and D.L. Felten, Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine treatment than young adults, Neurosci Lett 70 (1986), 326-331.
26. T.C. Iancu, H. Shiloh, K.B. Raja, R.J. Simpson, T.J. Peters, D.P. Perl, A. Hsu and P.F. Good, The hypotransferrinaemic mouse: ultrastructural and laser microprobe analysis observations, J Pathol 177 (1995), 83-94.
27. K. Jellinger, E. Kienzl, G. Rumpelmair, P. Riederer, H. Stachelberger, D. Ben-Shachar and M.B. Youdim, Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis, J Neurochem 59 ( 1992), 1168-1171.
28. P. Jenner, Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease, Acta Neurol Scand Suppl 146 (1993), 6-13.
29. P. Jenner, Presymptomatic detection of Parkinson's disease, J Neurol Transm Suppl 40 (1993), 23-36.
30. P. Jenner, Oxidative mechanisms in nigral cell death in Parkinson's disease, Mov Disord 13 (1998), 24-34.
31. N. Jha, O. Jurma, G. Lalli, Y. Liu, E.H. Pettus, J.T. Greenamyre, R.M. Liu, H.J. Forman and J.K. Andersen, Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity, Implications for Parkinson's disease, J Biol Chem 275 (2000), 26096-26101.
32. D. Kaur, F. Yantiri, S. Rajagopalan, J. Kumar, J.Q. Mo, R. Boonplueang, V. Viswanath, R. Jacobs, L. Yang, M.F. Beal et al., Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease, Neuron 37 (2003), 899-909.
33. P. Klivenyi, O.A. Andreassen, R.J. Ferrante, A. Dedeoglu, G. Mueller, E. Lancelot, M. Bogdanov, J.K. Andersen, D. Jiang and M.F. Beal, Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, J Neurosci 20 (2000), 1-7.
34. P. Klivenyi, O.A. Andreassen, R.J. Ferrante, E. Lancelot, D. Reif and M.F. Beal, Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity, Neuroreport 11 (2000), 1265-1268.
35. P. Klivenyi, D. St Clair, M. Wermer, H.C. Yen, T. Oberley, L. Yang and M. Flint Beal, Manganese superoxide dismutase overexpression attenuates MPTP toxicity, Neurobiol Dis 5 (1998), 253-258.
36. A.H. Koeppen, The history of iron in the brain, J Neurol Sci 134(Suppl) (1995), 1-9.
37. D.M. Kuhn, M. Sadidi, X. Liu, C. Kreipke, T. Geddes, C. Borges and J.T. Watson, Peroxynitrite-induced nitration of tyrosine hydroxylase: identification of tyrosines 423, 428, and 432 as sites of modification by matrix-assisted laser desorption ionization time-of-flight mass spectrometry and tyrosine-scanning mutagenesis, J Biol Chem 277 (2002), 14336-14342.
38. J. Lan and D.H. Jiang, Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice, J Neural Transm 104 (1997), 469-481.
39. J. Lan and D.H. Jiang, Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease, J Neural Transm 104 (1997), 649-660.
40. J.W. Langston, I. Irwin and L.E. DeLanney, The biotransformation of MPTP and disposition of MPP+: the effects of aging, Life Sci 40 (1987), 749-754.
41. X. Liu, M.J. Miller, M.S. Joshi, D.D. Thomas and J.R. Lancaster, Jr., Accelerated reaction of nitric oxide with O2 within the hydrophobic interior of biological membranes, Proc Natl Acad Sci USA 95 (1998), 2175-2179.
42. G. Logroscino, K. Marder, J. Graziano, G. Freyer, V. Slavkovich, N. Lojacono, L. Cote and R. Mayeux, Dietary iron, animal fats, and risk of Parkinson's disease, Mov Disord 13 (1998), 13-16.
43. B. Lonnerdal, Effects of maternal dietary intake on human milk composition, J Nutr 116 (1986), 499-513.
44. B. Lonnerdal, Effects of milk and milk components on calcium, magnesium, and trace elements absorption during infancy, Physiol Rev 77 (1997), 643-669.
45. G. Melino, F. Bernassola, R.A. Knight, M.T. Corasaniti, G. Nistico and A. Finazzi-Agro, S-nitrosylation regulates apoptosis, Nature 388 (1997), 432-433.
46. L. Molina y Vedia, B. McDonald, B. Reep, B. Brune, M. Di Silvio, T.R. Billiar and E.G. Lapetina, Nitric oxide-induced S-nitrosylation of glyceraldehyde-3-phosphate dehydrogenase inhibits enzymatic activity and increases endogenous ADP-ribosylation, J Biol Chem 267 (1992), 24929-24932.
47. V. Mulero and J.H. Brock, Regulation of iron metabolism in murine J774 macrophages: role of nitric oxide-dependent and -independent pathways following activation with gamma interferon and lipopolysaccharide, Blood 94 (1999), 2383-2389.
48. K. Nishi, T. Kondo and H. Narabayashi, Difference in recovery patterns of striatal dopamine content, tyrosine hydroxylase activity and total biopterin content after l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration: a comparison of young and older mice, Brain Res 489 (1989), 157-162.
49. K. Pantopoulos, Iron metabolism and the IRE/IRP regulatory system: an update, Ann NY Acad Sci 1012 (2004), 1-13.
50. R.K. Pearce, A. Owen, S. Daniel, P. Jenner and C.D. Marsden, Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease, J Neural Transm 104 (1997), 661-677.
51. T.L. Perry, D.V. Godin and S. Hansen, Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33 (1982), 305-310.
52. T.L. Perry and V.W. Yong, Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients, Neurosci Lett 67 (1986), 269-274.
53. J. Poirier, J. Donaldson and A. Barbeau, The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals, Biochem Biophys Res Commun 128 (1985), 25-33.
54. S. Przedborski, Q. Chen, M. Vila, B.I. Giasson, R. Djaldatti, S. Vukosavic, J.M. Souza, V.V. Jackson-Lewis, V.M. Lee and H. Ischiropoulos, Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease, J Neurochem 76 (2001), 637-640.
55. S. Przedborski, V. Kostic, V. Jackson-Lewis, A.B. Naini, S. Simonetti, S. Fahn, E. Carlson, C.J. Epstein and J.L. Cadet, Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity, J Neurosci 12 (1992), 1658-1667.
56. P. Rauhala, A.M. Lin and C.C. Chiueh, Neuroprotection by S-nitrosoglutathione of brain dopamine neurons from oxidative stress, FASEB J 12 (1998), 165-173.
57. G.A. Ricaurte, I. Irwin, L.S. Forno, L.E. DeLanney, E. Langston and J.W. Langston, Aging and l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra, Brain Res 403 (1987), 43-51.
58. G.A. Ricaurte, J.W. Langston, L.E. Delanney, I. Irwin, S.J. Peroutka and L.S. Forno, Fate of nigrostriatal neurons in young mature mice given 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment, Brain Res 376 (1986), 117-124.
59. P. Riederer, E. Sofic, W.D. Rausch, B. Schmidt, G.P. Reynolds, K. Jellinger and M.B. Youdim, Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains, J Neurochem 52 (1989), 515-520.
60. G. Sechi, M.G. Deledda, G. Bua, W.M. Satta, G.A. Deiana, G.M. Pes and G. Rosati, Reduced intravenous glutathione in the treatment of early Parkinson's disease, Prog Neuropsychopharmacol Biol Psychiatry 20 (1996), 1159-1170.
61. G.J. Sengstock, C.W. Olanow, A.J. Dunn and G.W. Arendash, Iron induces degeneration of nigrostriatal neurons, Brain Res Bull 28 (1992), 645-649.
62. G.J. Sengstock, C.W. Olanow, R.A. Menzies, A.J. Dunn and G.W. Arendash, (1993) Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers, J Neurosci Res 35, 67-82.
63. G.J. Sengstock, N.H. Zawia, C.W. Olanow, A.J. Dunn and G.W. Arendash, Intranigral iron infusion in the rat. Acute elevations in nigral lipid peroxidation and striatal dopaminergic markers with ensuing nigral degeneration, Biol Trace Elem Res 58 (1997), 177-195.
64. E. Soum, X. Brazzolotto, C. Goussias, C. Bouton, J.M. Moulis, T.A. Mattioli and J.C. Drapier, Peroxynitrite and nitric oxide differently target the iron-sulfur cluster and amino acid residues of human iron regulatory protein 1, Biochemistry 42 (2003), 7648-7654.
65. E. Soum and J.C. Drapier, Nitric oxide and peroxynitrite promote complete disruption of the [4Fe-4S] cluster of recombinant human iron regulatory protein 1, J Biol Inorg Chem 8 (2003), 226-232.
66. J.S. Stamler, L. Jia, J.P. Eu, T.J. McMahon, I.T. Demchenko, J. Bonaventura, K. Gernert and C.A. Piantadosi, Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient, Science 276 (1997), 2034-2037.
67. M. Takanashi, H. Mochizuki, K. Yokomizo, N. Hattori, H. Mori, Y. Yamamura and Y. Mizuno, Iron accumulation in the substantiel nigni of autosomal recessive juvenile parkinsonism (ARJP) 7 (2001), 311-314.
68. E.M. Taylor, A. Crowe and E.H. Morgan, Transferrin and iron uptake by the brain: effects of altered iron status, J Neurochem 57 (1991), 1584-1592.
69. E.M. Taylor and E.H. Morgan, Developmental changes in transferrin and iron uptake by the brain in the rat, Brain Res Dev Brain Res 55 (1990), 35-42.
70. K. Tieu, H. Ischiropoulos and S. Przedborski, Nitric oxide and reactive oxygen species in Parkinson's disease, IUBMB Life 55 (2003), 329-335.
71. J. Wang and K. Pantopoulos, Conditional derepression of ferritin synthesis in cells expressing a constitutive IRP1 mutant, Mol Cell Biol 22 (2002), 4638-4651.
72. R.J. Ward, D. Dexter, A. Florence, F. Aouad, R. Hider, P. Jenner and R.R. Crichton, Brain iron in the ferrocene-loaded rat: its chelation and influence on dopamine metabolism, Biochem Pharmacol 49 (1995), 1821-1826.
73. L. Xu, J.P. Eu, G. Meissner and J.S. Stamler, Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation, Science 279 (1998), 234-237.